A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Bristol-Myers Squibb
Celgene
Qilu Pharmaceutical Co., Ltd.
AbbVie
Antengene Corporation
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Karyopharm Therapeutics Inc
Amgen
Celgene
Celgene
Amgen
Qilu Pharmaceutical Co., Ltd.
Celgene
European Society for Blood and Marrow Transplantation
Case Comprehensive Cancer Center
Novartis
Celgene
AB Science
Celgene
Celgene
Alliance for Clinical Trials in Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Centocor, Inc.
Memorial Sloan Kettering Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
Northwestern University
Celgene
Nordic Myeloma Study Group
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Celgene